Clinical and biological effects of tumor-associated lymphocytes in the presence or absence of chemotherapy for malignant ascites in ovarian cancer patients.

about

Clinical and biological effects of tumor-associated lymphocytes in the presence or absence of chemotherapy for malignant ascites in ovarian cancer patients.

Item

http://www.wikidata.org/entity/Q41620209

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Clinical and biological effect ...... es in ovarian cancer patients.

@en

type

Item

label

Clinical and biological effect ...... es in ovarian cancer patients.

@en

prefLabel

Clinical and biological effect ...... es in ovarian cancer patients.

@en

P1476

Clinical and biological effect ...... es in ovarian cancer patients.

@en

P2093

Bin Ye

http://www.w3.org/2001/XMLSchema#string

Guolin Hu

http://www.w3.org/2001/XMLSchema#string

Kejun Liu

http://www.w3.org/2001/XMLSchema#string

Kelei Zhao

http://www.w3.org/2001/XMLSchema#string

Weijiang Liang

http://www.w3.org/2001/XMLSchema#string

Weiwei Zhang

http://www.w3.org/2001/XMLSchema#string

Yazhou Ren

http://www.w3.org/2001/XMLSchema#string

P2860

Adoptive immunotherapy for cancer: building on success

Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma

Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens

Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.

Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria

Pre-treatment with chemotherapy can enhance the antigenicity and immunogenicity of tumours by promoting adaptive immune responses

Clinical responses in a phase II study using adoptive transfer of short-term cultured tumor infiltration lymphocytes in metastatic melanoma patients.

Use of tumour-responsive T cells as cancer treatment.

CD8+ enriched "young" tumor infiltrating lymphocytes can mediate regression of metastatic melanoma.

Efficacy of adoptive cell transfer of tumor-infiltrating lymphocytes after lymphopenia induction for metastatic melanoma.

P304

3379-3386

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3892/OL.2017.6635

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-07-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28927091

http://www.w3.org/2001/XMLSchema#string

P921

ovarian cancer

P932

5587970

http://www.w3.org/2001/XMLSchema#string